vs

Side-by-side financial comparison of CarParts.com, Inc. (PRTS) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $120.4M, roughly 1.7× CarParts.com, Inc.). CarParts.com, Inc. runs the higher net margin — -9.6% vs -62.0%, a 52.4% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -9.8%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -8.6%).

Genuine Parts Company (GPC) is an American automotive and industrial parts distributor based in Atlanta, Georgia. Established by brothers Carlyle and Malcolm Fraser in 1928, the company has approximately 60,000 employees. In addition to the United States, GPC has operated in Australasia, Belgium, Canada, France, Germany, Mexico, the Netherlands, Poland, and the United Kingdom. GPC's subsidiaries include industrial parts distributor Motion as well as NAPA Auto Parts, which primarily sells part...

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

PRTS vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.7× larger
RARE
$207.3M
$120.4M
PRTS
Growing faster (revenue YoY)
RARE
RARE
+35.7% gap
RARE
25.9%
-9.8%
PRTS
Higher net margin
PRTS
PRTS
52.4% more per $
PRTS
-9.6%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-8.6%
PRTS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PRTS
PRTS
RARE
RARE
Revenue
$120.4M
$207.3M
Net Profit
$-11.6M
$-128.6M
Gross Margin
33.2%
Operating Margin
-54.7%
Net Margin
-9.6%
-62.0%
Revenue YoY
-9.8%
25.9%
Net Profit YoY
25.0%
3.5%
EPS (diluted)
$-0.82
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRTS
PRTS
RARE
RARE
Q4 25
$120.4M
$207.3M
Q3 25
$127.8M
$159.9M
Q2 25
$151.9M
$166.5M
Q1 25
$147.4M
$139.3M
Q4 24
$133.5M
$164.6M
Q3 24
$144.8M
$139.5M
Q2 24
$144.3M
$147.0M
Q1 24
$108.8M
Net Profit
PRTS
PRTS
RARE
RARE
Q4 25
$-11.6M
$-128.6M
Q3 25
$-10.9M
$-180.4M
Q2 25
$-12.7M
$-115.0M
Q1 25
$-15.3M
$-151.1M
Q4 24
$-15.4M
$-133.2M
Q3 24
$-10.0M
$-133.5M
Q2 24
$-8.7M
$-131.6M
Q1 24
$-170.7M
Gross Margin
PRTS
PRTS
RARE
RARE
Q4 25
33.2%
Q3 25
33.1%
Q2 25
32.8%
Q1 25
32.1%
Q4 24
32.5%
Q3 24
35.2%
Q2 24
33.5%
Q1 24
Operating Margin
PRTS
PRTS
RARE
RARE
Q4 25
-54.7%
Q3 25
-7.9%
-106.9%
Q2 25
-8.2%
-64.8%
Q1 25
-10.3%
-102.6%
Q4 24
-11.6%
-74.3%
Q3 24
-6.9%
-94.6%
Q2 24
-6.0%
-79.1%
Q1 24
-151.9%
Net Margin
PRTS
PRTS
RARE
RARE
Q4 25
-9.6%
-62.0%
Q3 25
-8.5%
-112.8%
Q2 25
-8.4%
-69.0%
Q1 25
-10.4%
-108.5%
Q4 24
-11.5%
-80.9%
Q3 24
-6.9%
-95.7%
Q2 24
-6.0%
-89.5%
Q1 24
-156.8%
EPS (diluted)
PRTS
PRTS
RARE
RARE
Q4 25
$-0.82
$-1.28
Q3 25
$-0.19
$-1.81
Q2 25
$-0.23
$-1.17
Q1 25
$-0.27
$-1.57
Q4 24
$-0.28
$-1.34
Q3 24
$-0.17
$-1.40
Q2 24
$-0.15
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRTS
PRTS
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$25.8M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$53.5M
$-80.0M
Total Assets
$184.9M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRTS
PRTS
RARE
RARE
Q4 25
$25.8M
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$150.6M
Q2 24
$480.7M
Q1 24
$112.3M
Stockholders' Equity
PRTS
PRTS
RARE
RARE
Q4 25
$53.5M
$-80.0M
Q3 25
$64.2M
$9.2M
Q2 25
$62.4M
$151.3M
Q1 25
$72.8M
$144.2M
Q4 24
$85.2M
$255.0M
Q3 24
$97.2M
$346.8M
Q2 24
$103.9M
$432.4M
Q1 24
$140.3M
Total Assets
PRTS
PRTS
RARE
RARE
Q4 25
$184.9M
$1.5B
Q3 25
$200.3M
$1.2B
Q2 25
$189.6M
$1.3B
Q1 25
$216.5M
$1.3B
Q4 24
$210.6M
$1.5B
Q3 24
$227.6M
$1.5B
Q2 24
$238.0M
$1.6B
Q1 24
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRTS
PRTS
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRTS
PRTS
RARE
RARE
Q4 25
$-99.8M
Q3 25
$-6.4M
$-91.4M
Q2 25
$-25.6M
$-108.3M
Q1 25
$5.5M
$-166.5M
Q4 24
$1.8M
$-79.3M
Q3 24
$8.5M
$-67.0M
Q2 24
$-3.6M
$-77.0M
Q1 24
$-190.7M
Free Cash Flow
PRTS
PRTS
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-8.3M
$-92.7M
Q2 25
$-27.9M
$-110.7M
Q1 25
$3.4M
$-167.8M
Q4 24
$-631.0K
$-79.5M
Q3 24
$4.9M
$-68.6M
Q2 24
$-10.8M
$-79.0M
Q1 24
$-193.9M
FCF Margin
PRTS
PRTS
RARE
RARE
Q4 25
-48.6%
Q3 25
-6.5%
-58.0%
Q2 25
-18.3%
-66.5%
Q1 25
2.3%
-120.5%
Q4 24
-0.5%
-48.3%
Q3 24
3.4%
-49.2%
Q2 24
-7.5%
-53.7%
Q1 24
-178.2%
Capex Intensity
PRTS
PRTS
RARE
RARE
Q4 25
0.5%
Q3 25
1.5%
0.8%
Q2 25
1.5%
1.5%
Q1 25
1.4%
1.0%
Q4 24
1.8%
0.1%
Q3 24
2.5%
1.2%
Q2 24
4.9%
1.4%
Q1 24
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRTS
PRTS

Segment breakdown not available.

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons